Weil is advising Sanofi in its agreement to acquire Dynavax Technologies Corporation, a publicly traded vaccines company with a marketed adult hepatitis B vaccine (HEPLISAV-B®) and a differentiated shingles vaccine candidate. Under the terms of the acquisition, Sanofi will commence a cash tender offer to acquire all outstanding shares of Dynavax for $15.50 per share in cash, reflecting a total equity value of approximately $2.2 billion. The acquisition augments Sanofi’s presence in adult immunization by bringing together Dynavax’s vaccines with Sanofi's global scale, development capabilities and commercial reach. Dynavax’s adult hepatitis B vaccine HEPLISAV-B is currently marketed in the U.S. and is differentiated by its two-dose regimen over one month, which enables high levels of seroprotection faster than other hepatitis B vaccines, which are given in three doses over six months.

The Weil team is led by Mergers & Acquisitions partners Michael J. Aiello and Sachin Kohli and includes counsel Christina De Vuono and associates Eileen Creaser, Josh Mackinnon and Megan Crocco; Executive Compensation & Benefits Head Paul Wessel and associates Nate Gross and Emily Warren; Technology & IP Transactions partner Kane Wishart and associate Adeline Park; Capital Markets partner Barbra Broudy and associate Federica Marini; Antitrust partner John Scribner and associate Drew Cypher; Regulatory Transactions partners Shawn Cooley, Antonia Tzinova and John O’Loughlin and associates Sisi Liu, Christina Carone and Caleb Holland; U.S. Privacy & Cybersecurity Head Olivia Greer and associate Taylor Peterson; Global Tax Chair Joe Pari and associate Madeline Joerg; Employment partner Xander Tabloff and associate Zeinab Bakillah; and Real Estate Co-Head Jannelle Seales and associate Adina Feder.